Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilars Statistical Guidance Reflects Early Development Approach

22 Sep 2017

• By Sue Sutter

Identical twins — Statistically, they are the same.

Related Content

Biosimilar Post-Approval Change Guidance Coming From US FDA

22 Sep 2017

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts

21 Sep 2017

Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests

22 Sep 2017

Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators

19 Jan 2017

US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry

01 Jun 2017

FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared

15 Jun 2015

Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis

11 Jul 2016

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences

15 Jul 2016

Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances

22 Sep 2016

Related Companies

Pfizer Inc.

Celltrion, Inc.

Johnson & Johnson

Novartis AG

Amgen, Inc.

Additional Topics

United States Biosimilars Research & Development Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.